Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review

Authors Suzanne A Ligthart, Eric P Moll van Charante, Willem A Van Gool, et al

Published Date August 2010 Volume 2010:6 Pages 775—785

DOI http://dx.doi.org/10.2147/VHRM.S7343

Published 17 August 2010

Suzanne A Ligthart1, Eric P Moll van Charante1, Willem A Van Gool2, Edo Richard2
1Department of General Practice, 2Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Background: Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, ­hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Keywords: cardiovascular risk factors, cognitive decline, dementia, prevention

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Are calcifying microvesicles another analogous substructure of calcifying nanoparticles?

Atughonu TC, Arja SB, Shiekh FA

International Journal of Nanomedicine 2013, 8:4673-4676

Published Date: 5 December 2013

Dengue: factors driving the emerging epidemic

Ali M

Clinical Epidemiology 2013, 5:461-463

Published Date: 19 November 2013

Erratum

Kawaji H, Ishii M, Tamaki Y, Sasaki K, Takagi M

Orthopedic Research and Reviews 2012, 4:103-104

Published Date: 8 November 2012

Corrigendum

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

Erratum

Utine CA

Clinical Ophthalmology 2011, 5:1415-1416

Published Date: 28 September 2011

Value of venous color flow duplex scan as initial screening test for geriatric inpatients with clinically suspected pulmonary embolism

Kreidy R, Stephan E, Salameh P, Waked M

Vascular Health and Risk Management 2011, 7:585-589

Published Date: 15 September 2011

Effects of safflower seed extract on arterial stiffness

Katsuya Suzuki, Shigekazu Tsubaki, Masami Fujita, et al

Vascular Health and Risk Management 2010, 6:1007-1014

Published Date: 3 November 2010

Early cardiovascular abnormalities in newly diagnosed obstructive sleep apnea

Jean-Philippe Baguet, Marie Nadra, Gilles Barone-Rochette, et al

Vascular Health and Risk Management 2009, 5:1063-1073

Published Date: 11 December 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Current management of type B aortic dissection

T Paul Tran, Ali Khoynezhad

Vascular Health and Risk Management 2009, 5:53-63

Published Date: 10 October 2008